Oppenheimer analyst Yigal Nochomovitz reiterated an Outperform-rated and boosted his price target on Ocular Therapeutix (NASDAQ: OCUL) to $49.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change FDA

Ocular Therapeutix (OCUL) Price Target Raised to $50 at RBCMarch 10, 2015 3:59 PM Ocular Therapeutix (OCUL) Announces OTX-DP Met Primary Endpoints in First Phase 3March 10, 2015 6:33 AM Ocular Therapeutix™ Reports Positive Topline Clinical Data for the First of Two Phase 3 Clinical Trials Evaluating OTX-DP for the Treatment of Post-Surgical Ocular Inflammation and PainMarch 10, 2015 6:30 AM